CV Death or First HF Hospitalization
Graphical Abstract · Panel Panel_B_bottom_
Panel Panel_B_bottom_ 是同一 Graphical Abstract 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Mingming Yang, Alasdair D Henderson, Inder S Anand, Akshay S Desai, Carolyn S P Lam, Aldo P Maggioni, Felipe A Martinez, Jean L Rouleau, Karl Swedberg, Muthiah Vaduganathan, Dirk J van Veldhuisen, Faiez Zannad, Michael R Zile, Milton Packer, Adel Rizkala, Eldrin F Lewis, Pardeep S Jhund, Scott D Solomon, John J V McMurray
Eur Heart J Cardiovasc Pharmacother 11(7) 574-589
AIMS: To investigate the EQ-5D-3L Level Sum Score (LSS) in patients with heart failure (HF) and reduced (HFrEF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and the effect of sacubitril/valsartan on this score using patient-level data from the PARADIGM-HF and PARAGON-HF trials. METHODS AND RESULTS: The LSS was calculated by summing the three levels (1-3) for each of the five domains (minimum sum score = 5; maximum sum score = 15). Patient characteristics and outcomes were compared across LSS tertiles (T1-T3) at baseline. Cox models were used to evaluate the primary endpoint [first HF hospitalization or cardiovascular death (CVD)] according to tertiles of LSS. Changes in LSS severity at 8 months were analysed using ordinal logistic regression models to estimate the effect of sacubitril/valsartan vs. enalapril or valsartan. Of 13 195 patients, 12 974 had a baseline LSS. Compared to lower LSS, patients with higher (worse) scores were older, more often women and White, and had more comorbidities and more severe HF. At 8 months, patients assigned to sacubitril/valsartan experienced more improvement and less worsening of LSS vs. the comparator: OR:1.16 (95%CI: 1.08-1.24). Sacubitril/valsartan also reduced the risk of the primary outcome across LSS tertiles: T1: HR: 0.87 (95%CI: 0.75-1.00); T2: 0.80 (95%CI: 0.71-0.90); T3: 0.87 (95%CI: 0.77-0.97); Pinteraction = 0.59. Higher LSS was independently associated with a greater risk of the primary endpoint, and the achieved LSS at 8 months may be more strongly associated with subsequent outcomes. CONCLUSION: Sacubitril/valsartan significantly reduced the risk of HF events and improved health status across the LSS spectrum in HFrEF and HFmrEF/HFpEF. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifiers: NCT01920711 (PARAGON-HF), NCT01035255 (PARADIGM-HF).
3 个 Figure · 16 个 KM 面板
Graphical Abstract Sacubitril/valsartan and health status measured using the EuroQol Five-Dimension Three-Level (EQ-5D-3L) questionnaire Level Sum Score (LSS) in patients with HFrEF and HFpEF. All the EQ-5D and severity levels contribute equally when calculating the LSS (A). Irrespective of HF phenotype, sacubitril/valsartan compared to a renin–angiotensin system (RAS) comparator (enalapril or valsartan) improved patient health status between baseline and 8 months as assessed with LSS (B-HFrEF and C-HFmrEF/HFpEF). Worse baseline EQ-5D-3L-LSS was associated with a higher risk of subsequent clinical outcomes. HF, heart failure; HFpEF, heart failure with preserved ejection fraction; OR, odds ratio; RAS, renin–angiotensin system.
Graphical Abstract · Panel Panel_B_bottom_
Panel Panel_B_bottom_ 是同一 Graphical Abstract 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Graphical Abstract · Panel Panel_C_bottom_
Panel Panel_C_bottom_ 是同一 Graphical Abstract 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 Cumulative incidence of the composite outcome according to baseline EuroQol Five-dimension Three-level (EQ-5D-3L) Questionnaire. ( A ) ‘Mobility’ domain; ( B ) ‘self-care’ domain; ( C ) ‘usual activities’ domain; ( D ) ‘pain/discomfort’ domain; ( E ) ‘anxiety/depression’ domain; ( F ) Level Sum Score (LSS) category divided by tertile; ( G ) Visual Analog Scale (VAS) category divided by tertile. The patients reported ‘Some problem’ and ‘Extreme problem’ were combined into one group due to a small number in the worst category of ‘mobility’ domain ( n = 27) and ‘self-care’ domain ( n = 73). CV, cardiovascular; HF, heart failure.
Figure 4 · Panel A
Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel B
Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel C
Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel D
Panel D 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel E
Panel E 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel F
Panel F 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4 · Panel G
Panel G 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 Cumulative incidence of all-cause death according to baseline EuroQol Five-dimension Three-level (EQ-5D-3L) Questionnaire. ( A ) ‘Mobility’ domain; ( B ) ‘self-care’ domain; ( C ) ‘usual activities’ domain; ( D ) ‘pain/discomfort’ domain; ( E ) ‘anxiety/depression’ domain; ( F ) Level Sum Score (LSS) category divided by tertile; ( G ) Visual Analog Scale (VAS) category divided by tertile. The patients reported ‘Some problem’ and ‘Extreme problem’ were combined into one group due to a small number in the worst category of ‘mobility’ domain ( n = 27) and ‘self-care’ domain ( n = 73).
Figure 5 · Panel A
Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel B
Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel C
Panel C 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel D
Panel D 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel E
Panel E 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel F
Panel F 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5 · Panel G
Panel G 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。